MitoPharm Corporation Discovers Biochemical Properties of Schisandrin B

SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pink Sheets:MTPM), reports today that chronic treatment with Schisandrin B, the precursor of "(-) Schisandrin B," can reverse mitochondrial aging in tissues of the brain, heart, liver and skeletal muscles. MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active.